Thioether monooxygenase mutant and application thereof in synthesis of esomeprazole
Through the directional evolution strategy, the sulfide monooxygenase mutant that efficiently utilizes NADH was developed, which solved the problems of low catalytic efficiency and poor stability in the existing technology, and achieved efficient and environmentally friendly synthesis of esomeprazole, suitable for industrial use. Production.
Patent Information
- Application Number
- CN202411160017.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-22
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-22
AI Technical Summary
The lack of biocatalysts that can efficiently utilize NADH for the synthesis of esomeprazole in the prior art, resulting in low catalytic efficiency, poor stability, low substrate tolerance and high coenzyme costs, making it difficult to meet industrial production needs.
Through directed evolutionary strategies such as error-prone PCR, site-directed mutations and combined mutations, a thioether monooxygenase mutant that efficiently utilizes coenzyme NADH was developed to improve its catalytic performance, and recombinant vectors were used to express recombinant vectors in Egypt Application in someprazole synthesis.
It has achieved efficient catalytic asymmetric oxidation of esomeprazole, with optical purity of the product greater than 99%, low coenzyme cost, high stability, high substrate concentration, mild reaction conditions, environmentally friendly, and good industrial application prospects.
Smart Images

Figure CN118909989A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of bioengineering, and specifically relates to a thioether monooxygenase mutant, a coding gene thereof, a recombinant expression vector containing the gene sequence, a co-expression recombinant vector and a recombinant expression transformant, a recombinant thioether monooxygenase mutant catalyst and a preparation method thereof, and application of the thioether monooxygenase mutant or the recombinant thioether monooxygenase mutant catalyst in the synthesis of esomeprazole. Background Art
[0002] Proton Pump Inhibitors (PPIs) are a class of special sulfoxide compounds containing benzimidazole, sulfinyl and pyridine rings, and are considered to be the best drugs for the treatment of gastroesophageal reflux disease (GERD). PPIs reduce gastric acid secretion by inhibiting the hydrogen-potassium ATPase pump, and have better efficacy, durability and safety than traditional histamine-H2 receptor antagonists (H2RA). Since the first PPI drug omeprazole was launched in Sweden in 1987, a variety of PPIs have been launched one after another, and now have become the most widely used drugs in the treatment of gastroesophageal related diseases. It is worth noting that chiral PPIs show stronger acid suppression strength, longer duration of action and higher bioavailability than racemic PPIs, and are gradually becoming the first choice for the treatment of gastric acid digestive diseases.
[0003] Esomeprazole, also known as (S)-omeprazole, is the S-configuration optical isomer of omeprazole and is the first chiral proton pump inhibitor (PPIs) to be marketed. Esomeprazole was developed by AstraZeneca and approved for marketing in 2001. Its chemical name is S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole. Currently, (S)-omeprazole magnesium trihydrate is mainly sold on the market. Compared with racemic omeprazole, esomeprazole exhibits superior clinical properties, with higher safety and efficacy, better gastric acid secretion control and symptom relief effects, longer duration of efficacy, and reduced frequency of administration. These advantages make esomeprazole one of the world's best-selling drugs and it occupies an important position in the treatment of digestive system diseases.
[0004] At present, the industrial production of PPIs mainly relies on chemical synthesis. However, this method has many defects: a large amount of organic solvents are used, the product refining steps are cumbersome, and wastewater and waste gas are easily generated, which not only affects the health of operators, but also has a negative impact on the environment. In addition, the use of expensive transition metal catalysts and the low stereoselectivity of the reaction further increase the production cost. The current industrial production of esomeprazole mainly has the following problems: chiral catalysts are expensive and stereoselective; a large amount of peracids, H2O2, organic catalysts and solvents are used, which harm the environment and personnel health; the reaction conditions are harsh, the production equipment requirements are high, and the cost increases. Therefore, in response to the needs of green production, the development of a biosynthetic method with high catalytic selectivity, mild reaction conditions, and green and efficient has become an important supplement to chemical synthesis.
[0005] Currently, the biosynthesis of esomeprazole mainly uses prochiral thioethers as substrates and utilizes whole-cell or free enzyme-catalyzed asymmetric oxidation. The reported biocatalysts include: (1) Cunninghamella echinulata MK40: can catalyze 7.5mM omeprazole sulfide, but the conversion rate is only 45% (Nagasawa T. Microbial synthesis of aprotonpump inhibitor by enantioselective oxidation of a sulfide into its corresponding sulfoxide by Cunninghamella echinulate MK40); 2) Lysinibacillus sp. B71 cells can catalyze 0.1g / L substrate with a conversion rate of 70% (Pavel Kyslík. Whole-cell oxidation ofomeprazole sulfide to enantiopure esomeprazole with Lysinibacillus sp. B71); (3) PAMO from Limnobacter sp.: can catalyze 50mM substrate through the whole cell (Juan Lin. "Nonpolarity paving" in substrate tunnel of a Limnobacter sp. Phenylacetone monooxygenase for efficient single whole-cell synthesis of esomeprazole); (4) Acinetobactercalcoaceticus NCIMB 9871 cyclohexanone monooxygenase mutant: can catalyze 100 g / L substrate, but freeze-dried enzyme powder needs to be added in batches (Codexis patent WO2011071982); (5) The mutant in patent CN108118035A: can catalyze 165 g / L substrate, but there are problems such as large enzyme dosage and poor tolerance.
[0006] Most monooxygenases (BVMOs) are NADPH-dependent. NADPH is more expensive and less stable than NADH, making it unsuitable for large-scale production. Therefore, more and more studies have been conducted on coenzymes. Reported studies on coenzyme modification include: (1) Modification of 4-hydroxyacetophenone monooxygenase (HAPMO) by sequence alignment analysis, which improved its catalytic performance for NADH by about 6.7 times (Albert JRHeck. Coenzyme Binding during Catalysis Is Beneficialfor the Stability of 4-Hydroxyacetophenone Monooxygenase); (2) Sequence alignment and structural analysis of phenylacetone monooxygenase (PAMO), which improved its catalytic performance for NADH by about 3.3 times (MarcoW.Fraaije. Investigating the coenzyme specificity of phenylacetonemonooxygenase from Thermobifida fusca). (3) Modification of cyclohexanone monooxygenase (CHMO) by sequence alignment and structural analysis. NCIMB9871 ) Through structural analysis, sequence comparison, and literature summary, the catalytic performance of NADH was improved by about 8 times (Uwe T. Bornscheuer. Switch in Cofactor Specificity of a Baeyer-Villiger Monooxygenase). At present, most of the above studies have solved the problem of coenzyme preference. Although the catalytic efficiency of NADH has been improved, the overall catalytic efficiency is too low, and its large-scale application is still limited.
[0007] The above studies show that although a variety of biocatalysts (such as BVMOs) have been developed for the synthesis of esomeprazole, they generally have problems such as low catalytic efficiency, poor stability, and low substrate tolerance. In addition, the cost of using the coenzyme NADPH is high and the stability is poor, making it difficult to meet the needs of industrial production. Therefore, the development of biocatalysts that efficiently utilize NADH is still an important research direction in this field. Summary of the invention
[0008] The purpose of the present invention is to solve the problem that there is a lack of a biocatalyst, thioether monooxygenase, that can efficiently utilize NADH and is used for the synthesis of esomeprazole in the prior art. The present application further provides a thioether monooxygenase mutant, a gene encoding the same, a recombinant expression vector containing the gene sequence, a co-expression recombinant vector 0 and a recombinant expression transformant, a recombinant thioether monooxygenase mutant catalyst and a preparation method thereof, and the use of the thioether monooxygenase mutant or the recombinant thioether monooxygenase mutant catalyst in the synthesis of esomeprazole.
[0009] The invention provides a thioether monooxygenase mutant with significantly improved catalytic synthesis of esomeprazole and capable of efficiently utilizing the coenzyme NADH by using directed evolution strategies such as error-prone PCR, site-directed mutagenesis and combined mutagenesis. The thioether monooxygenase mutant is used to catalyze the asymmetric oxidation of the substrate omeprazole thioether to synthesize esomeprazole, which has the significant advantages of low coenzyme cost, high stability, high substrate concentration, mild reaction conditions, environmental friendliness, high product yield and high optical purity.
[0010] The purpose of the present invention can be achieved by the following technical solutions:
[0011] One of the technical solutions of the present invention is: to provide a thioether monooxygenase mutant, that is, to provide an isolated protein that can be used as a thioether monooxygenase, the parent of the mutant is AcPSMO, and the enzyme is derived from Acinetobactercalcoaceticus; the encoding gene of AcPSMO is shown in SEQ ID No.1, and the amino acid sequence of AcPSMO is shown in SEQ ID No.2.
[0012] The thioether monooxygenase mutant replaces one or more of the amino acid residues at position 56 Ser, position 70 Glu, position 123 Asn, position 128 Asn, position 133 Thr, position 143 Leu, position 145 Ala, position 146 Ala, position 148 Asn, position 149 Leu, position 151 Lys, position 207 Arg, position 208 Ser, position 209 Ala, position 210 Gln, position 349 Lys, position 376 Cys, and position 526 Lys of the amino acid sequence shown in SEQ ID No. 2 with other amino acid residues to form a protein corresponding to a new amino acid sequence.
[0013] Preferably, the thioether monooxygenase mutant has one of the following sequences:
[0014] (1) replacing Ser at position 56 of the amino acid sequence shown in SEQ ID No. 2 with Val;
[0015] (2) replacing Glu at position 70 of the amino acid sequence shown in SEQ ID No. 2 with Thr;
[0016] (3) replacing Asn at position 123 of the amino acid sequence shown in SEQ ID No. 2 with Arg;
[0017] (4) replacing Asn at position 128 of the amino acid sequence shown in SEQ ID No. 2 with His;
[0018] (5) replacing Thr at position 133 of the amino acid sequence shown in SEQ ID No. 2 with Leu;
[0019] (6) replacing Leu at position 143 of the amino acid sequence shown in SEQ ID No. 2 with Phe;
[0020] (7) replacing Ala at position 145 of the amino acid sequence shown in SEQ ID No. 2 with Gly;
[0021] (8) replacing Ala at position 146 of the amino acid sequence shown in SEQ ID No. 2 with Arg;
[0022] (9) replacing Asn at position 148 of the amino acid sequence shown in SEQ ID No. 2 with Trp;
[0023] (10) replacing Leu at position 149 of the amino acid sequence shown in SEQ ID No. 2 with Phe;
[0024] (11) replacing Lys at position 151 of the amino acid sequence shown in SEQ ID No. 2 with Arg;
[0025] (12) replacing Arg at position 207 of the amino acid sequence shown in SEQ ID No. 2 with Lys;
[0026] (13) replacing Ser at position 208 of the amino acid sequence shown in SEQ ID No. 2 with Asp;
[0027] (14) replacing Ala at position 209 of the amino acid sequence shown in SEQ ID No. 2 with Val;
[0028] (15) replacing Gln at position 210 of the amino acid sequence shown in SEQ ID No. 2 with Leu;
[0029] (16) replacing Lys at position 349 of the amino acid sequence shown in SEQ ID No. 2 with Arg;
[0030] (17) replacing Cys at position 376 of the amino acid sequence shown in SEQ ID No. 2 with Pro;
[0031] (18) replacing Lys at position 526 of the amino acid sequence shown in SEQ ID No. 2 with His;
[0032] (19) The 56th Ser in the amino acid sequence shown in SEQ ID No. 2 is replaced by Val, and the 143rd Leu is replaced by Phe;
[0033] (20) the Asn at position 123 of the amino acid sequence shown in SEQ ID No. 2 is replaced by Arg, and the Ala at position 145 is replaced by Gly;
[0034] (21) the Asn at position 128 of the amino acid sequence shown in SEQ ID No. 2 is replaced by His, and the Ala at position 146 is replaced by Arg;
[0035] (22) replacing Leu at position 149 with Phe and Ser at position 208 with Asp in the amino acid sequence shown in SEQ ID No. 2;
[0036] (23) the 151st Lys of the amino acid sequence shown in SEQ ID No. 2 is replaced by Arg, and the 210th Gln is replaced by Leu;
[0037] (24) The 349th Lys in the amino acid sequence shown in SEQ ID No. 2 is replaced by Arg, and the 526th Lys is replaced by His;
[0038] (25) in the amino acid sequence shown in SEQ ID No. 2, the Ser at position 56 is replaced by Val, the Leu at position 143 is replaced by Phe, and the Lys at position 349 is replaced by Arg;
[0039] (26) in the amino acid sequence shown in SEQ ID No. 2, Glu at position 70 is replaced by Thr, Asn at position 148 is replaced by Trp, and Cys at position 376 is replaced by Pro;
[0040] (27) in the amino acid sequence shown in SEQ ID No. 2, Ser at position 56 is replaced by Val, Leu at position 143 is replaced by Phe, Lys at position 349 is replaced by Arg, and Cys at position 376 is replaced by Pro;
[0041] (28) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, and Ser at position 208 is replaced by Asp;
[0042] (29) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 128 is replaced by His, Ala at position 146 is replaced by Arg, Ala at position 209 is replaced by Val, and Gln at position 210 is replaced by Leu;
[0043] (30) in the amino acid sequence shown in SEQ ID No. 2, Ser at position 56 is replaced by Val, Leu at position 143 is replaced by Phe, Lys at position 349 is replaced by Arg, Cys at position 376 is replaced by Pro, and Lys at position 526 is replaced by His;
[0044] (31) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, and Lys at position 349 is replaced by Arg;
[0045] (32) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 128 is replaced by His, Ala at position 146 is replaced by Arg, Ala at position 209 is replaced by Val, Gln at position 210 is replaced by Leu, and Lys at position 151 is replaced by Arg;
[0046] (33) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, Lys at position 349 is replaced by Arg, and Leu at position 143 is replaced by Phe;
[0047] (34) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, Lys at position 349 is replaced by Arg, Leu at position 143 is replaced by Phe, and Ser at position 56 is replaced by Val;
[0048] (35) In the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, Lys at position 349 is replaced by Arg, Leu at position 143 is replaced by Phe, Ser at position 56 is replaced by Val, and Lys at position 526 is replaced by His.
[0049] The preparation method of the protein of the present invention is a conventional preparation method in the art. The preparation method is preferably: cloning a nucleic acid molecule encoding the protein and having a point mutation into an expression vector, transforming the obtained recombinant vector into an expression host, obtaining a recombinant expression transformant; culturing the obtained recombinant expression transformant, and separating and purifying to obtain the protein. The preparation method can also be obtained by artificially synthesizing the sequence of the protein.
[0050] The second technical solution of the present invention is to provide a nucleic acid of the above-mentioned thioether monooxygenase mutant. The nucleic acid encodes and expresses the thioether monooxygenase mutant obtained by evolutionary modification as in the technical solution one, and its source includes: cloning the gene sequence of the thioether monooxygenase mutant as in the technical solution one by genetic engineering technology; or obtaining the nucleic acid molecule encoding the thioether monooxygenase mutant as in the technical solution one by artificial full sequence synthesis method.
[0051] The third technical solution of the present invention is to provide a recombinant expression vector comprising the above-mentioned thioether monooxygenase mutant nucleic acid. The recombinant expression vector can be constructed by connecting the nucleic acid sequence encoding the thioether monooxygenase mutant of the present invention to various commercially available empty vectors by conventional methods in the art.
[0052] Furthermore, the commercially available empty vector can be any conventional plasmid vector in the art, as long as the recombinant expression vector can be normally replicated in the corresponding expression host and express the corresponding thioether monooxygenase. For different expression hosts, the preferred plasmid vector is different. Those skilled in the art are aware of how to select appropriate vectors, promoters, enhancers and host cells.
[0053] Furthermore, for the E. coli host, the plasmid vector is preferably a pET-28a(+) plasmid. The E. coli recombinant expression plasmid of the present invention can be obtained by the following method: the gene DNA fragment of the thioether monooxygenase mutant obtained by PCR amplification is double-digested with restriction endonucleases Nde I and Hind III, and the empty plasmid pET-28a(+) is also double-digested with restriction endonucleases Nde I and Hind III, the DNA fragment of the thioether monooxygenase mutant after the above digestion and the empty plasmid are recovered, and connected by T4 DNA ligase to obtain a recombinant expression plasmid containing the thioether monooxygenase mutant encoding nucleic acid for E. coli expression.
[0054] The fourth technical solution of the present invention is to provide a co-expression recombinant vector comprising the thioether monooxygenase mutant gene and the dehydrogenase gene of the present invention.
[0055] Furthermore, for the E. coli host, the present invention chooses to use the homologous recombination method to construct two segments of the target gene in pETDuet-1 containing two multiple cloning sites. The E. coli recombinant expression plasmid described in the present invention can be prepared by the following method: first, the target plasmid of the dehydrogenase is used as a PCR amplification template, and the target fragment required by this application is amplified using PrimerSTAR Max high-fidelity polymerase, and then the pETDuet-1 plasmid is used as a template to reversely amplify the linearized vector fragment, and it is inserted into the MCS1 multiple cloning site of the pETDuet-1 plasmid using homologous recombination; then the target gene of AcPSMO is amplified, recovered according to the same method, and inserted into the MCS2 multiple cloning site of the pETDuet-1 plasmid using homologous recombination, and then verified by transformation sequencing.
[0056] A fifth technical solution of the present invention is to provide a recombinant expression transformant comprising the thioether monooxygenase mutant gene, its recombinant expression vector or its co-expression recombinant vector described in the above technical solution of the present invention.
[0057] Furthermore, the recombinant expression transformant can be prepared by transforming the recombinant expression vector constructed in Technical Solution 3 or the co-expression recombinant vector constructed in Technical Solution 4 into a host cell. The host cell is any conventional host cell in the art, as long as the recombinant expression vector can stably replicate itself therein and can effectively express the target protein after being induced by an inducer; the present invention preferably uses Escherichia coli as the host cell, and more preferably Escherichia coli BL21 (DE3) is used to efficiently express the thioether monooxygenase mutant of the present invention.
[0058] The sixth technical solution of the present invention is to provide a recombinant thioether monooxygenase mutant catalyst, wherein the recombinant thioether monooxygenase mutant catalyst is any one of the following forms:
[0059] (1) culturing the recombinant expression transformant of the present invention, and isolating transformant cells containing the thioether monooxygenase mutant;
[0060] (2) culturing the recombinant expression transformant of the present invention, isolating and crushing the crude enzyme solution containing the thioether monooxygenase mutant;
[0061] (3) Cultivating the recombinant expression transformant of the present invention, isolating and crushing the thioether monooxygenase mutant to obtain a crude enzyme solution, and freeze-drying the crude enzyme solution to obtain a crude enzyme powder.
[0062] Furthermore, the culture method and conditions of the recombinant expression transformant are conventional methods and conditions in the art, which include the following steps: culturing the recombinant expression transformant of the present invention to obtain recombinant thioether monooxygenase. For recombinant Escherichia coli, the preferred culture medium is LB medium: peptone 10g / L, yeast extract 5g / L, NaCl 10g / L, pH 6.5-7.0. The preferred culture method is: inoculate the recombinant Escherichia coli as described above into LB medium containing kanamycin, and culture overnight at 37°C and 180rpm with shaking. The seed liquid is inoculated into a 5L fermentation tank containing 3L LB medium (containing kanamycin), and the dissolved oxygen (DO) is controlled to be above 30% by adjusting the stirring speed and adding carbon and nitrogen sources. When the OD of the culture solution is 600 When the temperature reaches 8-10, add isopropyl-β-D-thiogalactoside (IPTG) with a final concentration of 0.1-0.5mmol / L as an inducer, and after induction at 16-25°C for 8-24h, centrifuge the culture solution, collect the cells, and then wash twice with physiological saline to obtain recombinant expression transformant cells. The harvested recombinant cells are freeze-dried to obtain freeze-dried cells containing the thioether monooxygenase mutant. The harvested recombinant cells are suspended in a buffer solution with a volume of 5-10 times (v / w), ultrasonically broken, and centrifuged to collect the supernatant to obtain the crude enzyme solution of the recombinant thioether monooxygenase mutant. The collected crude enzyme solution is placed at -80°C and frozen, and then low-temperature dried using a vacuum freeze dryer to obtain the freeze-dried enzyme powder of the recombinant thioether monooxygenase mutant. The obtained freeze-dried cells or freeze-dried enzyme powder are stored in a 4°C refrigerator for convenient use.
[0063] The seventh technical solution of the present invention is to provide an application of a thioether monooxygenase mutant or a recombinant thioether monooxygenase mutant catalyst. The application uses omeprazole thioether as a substrate, and uses the thioether monooxygenase mutant or the recombinant thioether monooxygenase mutant catalyst to catalyze the synthesis of esomeprazole (such as omeprazole thioether) from omeprazole thioether.Figure 1 shown).
[0064] The application is carried out in phosphate buffer and requires the coenzyme NADH or NAD + The application also requires the presence of at least one of glucose, sodium formate, isopropanol and its corresponding dehydrogenase.
[0065] Preferably, the concentration of the substrate omeprazole sulfide of the present invention is 1-30 g / L, the amount of glucose, sodium formate or isopropanol is 1.5-45 g / L, and the coenzyme NADH or NAD + The dosage is 0.1-0.5 mM; the dosage of the thioether monooxygenase mutant or recombinant thioether monooxygenase mutant catalyst is 10-800 U / L, and the dosage of the dehydrogenase is 15-1200 U / L; the reaction progress can be monitored by conventional detection methods in the art, such as liquid chromatography HPLC or thin plate chromatography TLC, and the reaction time is based on the time when the substrate concentration no longer decreases or the product concentration no longer increases.
[0066] Compared with the prior art, the innovative advantages and improved effects of the present invention are at least:
[0067] 1. The present invention provides a thioether monooxygenase mutant that can efficiently utilize the coenzyme NADH and has better catalytic performance, which can efficiently catalyze the asymmetric oxidation reaction of esomeprazole to prepare optically pure esomeprazole.
[0068] 2. The thioether monooxygenase mutant can catalyze the asymmetric oxidation of 30 g / L esomeprazole, achieving a conversion rate of more than 99%, and the optical purity of the product is greater than 99%.
[0069] 3. Compared with other thioether monooxygenases, the thioether monooxygenase mutant obtained in the present invention has the advantages of high catalytic activity of coenzyme NADH, high endogenous content of coenzyme NADH in cells, strong stability, large substrate loading capacity, high yield, low production cost and environmental friendliness, and therefore has good industrial application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] Figure 1 Schematic diagram of the synthesis of esomeprazole using omeprazole sulfide as substrate;
[0071] Figure 2 This is the chromatogram of the standard product measured by HPLC in Example 6;
[0072] Figure 3 This is the chromatogram of the substrate and product in the sample measured by HPLC in Example 6. DETAILED DESCRIPTION
[0073] Each reaction or detection condition described in the content of the present invention can be combined or changed according to the common sense in the art, and can be verified by experiments. The technical scheme and technical effects of the present invention will be clearly and completely described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited to these embodiments, and any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.
[0074] The sources of materials in the following examples are:
[0075] The recombinant plasmids pET28a-AcPSMO and pETDuet-1-(AGF)DH-AcPSMO contain the nucleic acid sequence shown in SEQ ID No. 1 in the sequence listing, which are constructed by the inventors themselves and are also disclosed in patent CN 202310650468.
[0076] Empty plasmid vector pET-28a was purchased from Novagen; empty plasmid vector pETDuet-1 was purchased from Novagen; E. coli BL21 (DE3) competent cells, 2× Taq PCR MasterMix, and agarose gel DNA recovery kit were all purchased from Beijing Tiangen Biochemical Technology Co., Ltd.; restriction endonucleases Nde I, Hind III, and T4 DNA ligase were all commercially available products from New England Biolabs (NEB); fast PCR polymerase Max DNA Polymerase is a commercially available product from TaKaRa.
[0077] Unless otherwise stated, the specific experiments in the following examples were performed according to conventional methods and conditions in the art, or in accordance with the commercial instructions of the kits.
[0078] Example 1: Construction of a random mutation library of thioether monooxygenase (AcPSMO)
[0079] The error-prone PCR technique was used to randomly mutate the nucleotide sequence of the thioether monooxygenase encoded by SEQ ID No. 1 in the sequence table.
[0080] Used Upstream primer The upstream primer and the downstream primer are shown as SEQ ID No.3 and SEQ ID No.4 respectively, wherein the CCATAT sequence in the upstream primer is the restriction site of Nde I, and the AAGCTT sequence in the downstream primer is the restriction site of HindⅢ.
[0081] Using pET28a-AcPSMO as template, error-prone PCR was performed with rTaq DNA polymerase to construct a random mutation library. PCR system (50 μL): 0.5 μL rTaq DNA polymerase, 10× PCR buffer (Mg 2+ Plus) 5.0μL, dNTP Mixture (each 2.0mM) 4.0μL, MnCl2 with a final concentration of 80μmol / L, pET28a-AcPSMO plasmid 0.5ng, upstream and downstream primers (10μM) 2μL each, add sterile distilled water to make up to 50μL. PCR reaction procedure: (1) 95℃ pre-denaturation for 5min; (2) 94℃ denaturation for 30s; (3) 58℃ annealing for 30s; (4) 72℃ extension for 1min; steps (2) to (4) are repeated for 30 cycles; finally, 72℃ extension for 10min, and the product is stored at 4℃. The PCR product is verified by agarose gel electrophoresis analysis and then purified and recovered. The recovered target gene DNA fragment and empty plasmid pET28a are double-digested with restriction endonucleases Nde I and HindⅢ at 37℃ for 12h. The double-digestion product was verified by agarose gel electrophoresis analysis and then purified and recovered. The linearized pET28a plasmid obtained was connected with the purified target gene DNA fragment at 16°C overnight using T4 DNA ligase. The ligation product was transformed into E. coli BL21 (DE3) competent cells and evenly spread on LB agar plates containing 50 μg / mL kanamycin, and placed in a 37°C incubator for about 12 hours.
[0082] The transformants on the transformation plate were picked into a 96-well deep-well plate using the monoclonal automatic picker Qpix450 of Molecular Devices (Shanghai) Co., Ltd. and cultured overnight at 20-30°C and 800rpm in a shaker. 50μL of bacterial solution was drawn from the primary plate wells using the TECAN fully automated liquid handling workstation (Freedom EVO) and inoculated into the corresponding secondary plate wells. After culturing at 20-30°C and 800rpm in a shaker for 5-10h, the culture was induced at 20-30°C for 72h. Then, the supernatant was taken for high-throughput screening of the expressed proteins in a 96-well plate, and the mutants with higher activity against omeprazole thioether were purified and characterized, and the corresponding genes were sequenced.
[0083] The high-throughput activity screening assay method of the AcPSMO mutant is as follows: 1 mM substrate omeprazole thioether, 1 mM coenzyme NADH potassium phosphate buffer (100 mM, pH 9.0), 100 mM cosubstrate and a certain amount of dehydrogenase powder are dispensed into a 96-well plate, preheated to 30° C., and then appropriate amounts of AcPSMO mutant secretion supernatant are added respectively, and the reaction is shaken at 30° C. The absorbance change of NADH at 360 nm is detected on a microplate reader, the absorbance change value within 3 minutes is recorded, and the corresponding enzyme activity is calculated.
[0084] Example 2 Semi-rational design of AcPSMO mutants using NADH enhancement
[0085] The amino acids near the coenzyme binding site of AcPSMO were selected for mutation, and upstream primers and downstream primers were designed according to the sequence of AcPSMO, as shown in Table 1. The primer sequences refer to SEQ ID No. 5 to 24 in sequence.
[0086] Table 1. Primer sequences for thioether monooxygenase AcPSMO
[0087]
[0088]
[0089] Using pET28a-AcPSMO as template, PrimeStar Max polymerase was used for PCR to construct mutant library. PCR system (25 μL): PrimeStar Max polymerase 12.5 μL, pET28a-AcPSMO plasmid 0.5 μL, upstream and downstream primers (10 μM) 0.5 μL each, DMSO 0.5 μL and sterile distilled water to make up to 25 μL. PCR reaction procedure: (1) 95℃ pre-denaturation for 5 min; (2) 98℃ denaturation for 10 s; (3) 60℃ annealing for 10 s; (4) 72℃ extension for 1 min 20 s; steps (2) to (4) were performed for a total of 39 cycles; finally, 72℃ extension for 5 min, and the product was stored at 4℃. The obtained product was added with 1 μL of Dpn I, and then incubated at 37°C for 1 hour, and the digestion product was transformed into E. coli BL21 (DE3) competent cells, and evenly spread on LB agar plates containing 50 μg / mL kanamycin, and placed in a 37°C incubator for static culture for about 12 hours. The remaining operations are as shown in Example 1.
[0090] Example 3 Combination mutations of beneficial mutants of AcPSMO
[0091] On the basis of the mutations in Example 1 and Example 2, a plurality of mutants with advantages in utilizing NADH activity were obtained, and the relevant mutation sites involved in the obtained advantageous mutants were combined by site-directed mutagenesis.
[0092] PCR system (25 μL): PrimeStar Max polymerase 12.5 μL, pET28a-AcPSMO plasmid 0.5 μL, upstream and downstream primers (10 μM) 0.5 μL each, DMSO 0.5 μL, add sterile distilled water to make up to 25 μL. PCR reaction procedure: (1) 95°C pre-denaturation for 5 min; (2) 98°C denaturation for 10 s; (3) 60°C annealing for 10 s; (4) 72°C extension for 1 min 20 s; steps (2) to (4) were performed for a total of 39 cycles; finally, 72°C extension for 5 min, and the product was stored at 4°C. The obtained product was added with 1 μL of Dpn I, and then incubated at 37°C for 1 h. The digested product was transformed into E. coli BL21 (DE3) competent cells and evenly spread on LB agar plates containing 50 μg / mL kanamycin, and placed in a 37°C incubator for static culture for about 12 h.
[0093] Example 4 Construction of a co-expression system of recombinant thioether monooxygenase and dehydrogenase
[0094] In this example, the M25-M35 dominant mutants obtained in Example 3 were used to construct a co-expression system. Using pET28a-AcPSMO and pET28a-dehydrogenase as templates, PrimeStar Max polymerase was used for PCR to extract the target gene. PCR system (25 μL): PrimeStar Max polymerase 12.5 μL, pET28a-AcPSMO plasmid 0.5 μL, upstream and downstream primers (10 μM) 0.5 μL each, DMSO 0.5 μL plus sterile distilled water to make up to 25 μL. PCR reaction procedure: (1) 95°C pre-denaturation for 5 min; (2) 98°C denaturation for 10 s; (3) 60°C annealing for 10 s; (4) 72°C extension for 20 s; steps (2) to (4) were performed for a total of 39 cycles; finally, 72°C extension for 5 min, and the product was stored at 4°C.
[0095] The pETDuet-1 plasmid was used as a template to reversely amplify the linearized vector fragment. After the target fragment and the linearized vector were successfully amplified, the PCR product of the linearized vector was digested with Dpn I and the product was recovered by gel electrophoresis. Then, the target fragment: linearized vector was mixed in a ratio of 2:1 and the homologous recombinase was added. After incubation at 50°C for 30 minutes, the recombinant product was obtained and transformation verification was performed. The two genes were respectively inserted into the pETDuet-1 plasmid.
[0096] Example 5 Purification of recombinant thioether monooxygenase mutants
[0097] 1.0 g of resting cells of the recombinant thioether monooxygenase mutant were resuspended in 10 mL of buffer (liquid A), and ultrasonically disrupted in an ice-water bath: 400 W power, 4 s working, 6 s rest, 99 cycles, centrifuged at 15000 rpm for 40 minutes at 4 ° C, and the supernatant was collected and protein purified by nickel column affinity chromatography. The following is the buffer formula: solution A: KPB buffer (20 mM, pH 7.5), containing 0.5 M NaCl, 10 mM imidazole; solution B: KPB buffer (20 mM, pH 7.5), containing 0.5 M NaCl, 0.5 M imidazole; solution C: KPB buffer (25 mM, pH 7.5), 150 mM NaCl, 1 mM DTT. The crude enzyme solution of thioether monooxygenase was loaded onto a nickel column, and impurities were first eluted with solution A, followed by the target protein elution with solution B. The eluate was concentrated to a certain volume by ultrafiltration and then replaced with solution C to reduce the imidazole concentration in the protein solution. The purified protein was collected according to the results of SDS-PAGE detection, glycerol was added at a final concentration of 20% (w / v), and it was quickly frozen with liquid nitrogen and stored at -80°C for later use.
[0098] Example 6 Activity determination of recombinant thioether monooxygenase mutants
[0099] The enzyme activity of AcPSMO towards omeprazole thioether substrate was determined as follows: 0.2 mM omeprazole thioether substrate and 0.2 mM NADH were added to 0.5 mL reaction system (0.1 M KPB buffer, pH 9.0), and an appropriate amount of pure enzyme solution was added, which was quickly mixed. The reaction was carried out at 30 ° C and 1000 rpm for 10 min, and the reaction was terminated and extracted with 0.5 mL ethyl acetate. The supernatant was filtered through a 0.22 μm pore size filter membrane and then subjected to liquid phase analysis to determine the conversion rate of the substrate and the ee of the product.
[0100] The specific analysis conditions for substrate conversion rate and ee are as follows:
[0101] Instrument: Shimadzu HPLC 2010A; Column model: Chiralpak IA; Mobile phase: n-heptane: ethanol = 70:30 (v / v); Flow rate: 0.5 mL min -1 ; Column temperature: 40℃; Injection volume: 10μL; Detector: UV detector; Detection wavelength: 300nm.
[0102] The enzyme activity unit (U) is defined as the amount of enzyme required to catalyze the conversion of 1 μmol of omeprazole thioether substrate to (S)-omeprazole per minute under the above conditions.
[0103] In the list of Table 2, the sequence numbers refer to the corresponding sequences described above. In the activity column using NADH as a hydrogen donor, one plus sign "+" indicates that the specific activity of the mutant protein is 1.0 to 2.0 times higher than that of the protein composed of the amino acid sequence shown in SEQ ID No. 2 in the sequence list; two plus signs "++" indicate that the specific activity of the mutant protein is 2.1 to 4.0 times higher than that of the protein composed of the amino acid sequence shown in SEQ ID No. 2; three plus signs "+++" indicate that the specific activity of the mutant protein is 4.1 to 8.0 times higher than that of the protein composed of the amino acid sequence shown in SEQ ID No. 2.
[0104] Table 2 List of thioether monooxygenase mutant sequences and corresponding activity improvements
[0105]
[0106]
[0107] The amino acid sequences of the thioether monooxygenase mutants corresponding to the sequence numbers are as follows:
[0108] (1) replacing Ser at position 56 of the amino acid sequence shown in SEQ ID No. 2 with Val;
[0109] (2) replacing Glu at position 70 of the amino acid sequence shown in SEQ ID No. 2 with Thr;
[0110] (3) replacing Asn at position 123 of the amino acid sequence shown in SEQ ID No. 2 with Arg;
[0111] (4) replacing Asn at position 128 of the amino acid sequence shown in SEQ ID No. 2 with His;
[0112] (5) replacing Thr at position 133 of the amino acid sequence shown in SEQ ID No. 2 with Leu;
[0113] (6) replacing Leu at position 143 of the amino acid sequence shown in SEQ ID No. 2 with Phe;
[0114] (7) replacing Ala at position 145 of the amino acid sequence shown in SEQ ID No. 2 with Gly;
[0115] (8) replacing Ala at position 146 of the amino acid sequence shown in SEQ ID No. 2 with Arg;
[0116] (9) replacing Asn at position 148 of the amino acid sequence shown in SEQ ID No. 2 with Trp;
[0117] (10) replacing Leu at position 149 of the amino acid sequence shown in SEQ ID No. 2 with Phe;
[0118] (11) replacing Lys at position 151 of the amino acid sequence shown in SEQ ID No. 2 with Arg;
[0119] (12) replacing Arg at position 207 of the amino acid sequence shown in SEQ ID No. 2 with Lys;
[0120] (13) replacing Ser at position 208 of the amino acid sequence shown in SEQ ID No. 2 with Asp;
[0121] (14) replacing Ala at position 209 of the amino acid sequence shown in SEQ ID No. 2 with Val;
[0122] (15) replacing Gln at position 210 of the amino acid sequence shown in SEQ ID No. 2 with Leu;
[0123] (16) replacing Lys at position 349 of the amino acid sequence shown in SEQ ID No. 2 with Arg;
[0124] (17) replacing Cys at position 376 of the amino acid sequence shown in SEQ ID No. 2 with Pro;
[0125] (18) replacing Lys at position 526 of the amino acid sequence shown in SEQ ID No. 2 with His;
[0126] (19) The 56th Ser in the amino acid sequence shown in SEQ ID No. 2 is replaced by Val, and the 143rd Leu is replaced by Phe;
[0127] (20) the Asn at position 123 of the amino acid sequence shown in SEQ ID No. 2 is replaced by Arg, and the Ala at position 145 is replaced by Gly;
[0128] (21) the Asn at position 128 of the amino acid sequence shown in SEQ ID No. 2 is replaced by His, and the Ala at position 146 is replaced by Arg;
[0129] (22) replacing Leu at position 149 with Phe and Ser at position 208 with Asp in the amino acid sequence shown in SEQ ID No. 2;
[0130] (23) the 151st Lys of the amino acid sequence shown in SEQ ID No. 2 is replaced by Arg, and the 210th Gln is replaced by Leu;
[0131] (24) The 349th Lys in the amino acid sequence shown in SEQ ID No. 2 is replaced by Arg, and the 526th Lys is replaced by His;
[0132] (25) in the amino acid sequence shown in SEQ ID No. 2, the Ser at position 56 is replaced by Val, the Leu at position 143 is replaced by Phe, and the Lys at position 349 is replaced by Arg;
[0133] (26) in the amino acid sequence shown in SEQ ID No. 2, Glu at position 70 is replaced by Thr, Asn at position 148 is replaced by Trp, and Cys at position 376 is replaced by Pro;
[0134] (27) in the amino acid sequence shown in SEQ ID No. 2, Ser at position 56 is replaced by Val, Leu at position 143 is replaced by Phe, Lys at position 349 is replaced by Arg, and Cys at position 376 is replaced by Pro;
[0135] (28) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, and Ser at position 208 is replaced by Asp;
[0136] (29) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 128 is replaced by His, Ala at position 146 is replaced by Arg, Ala at position 209 is replaced by Val, and Gln at position 210 is replaced by Leu;
[0137] (30) in the amino acid sequence shown in SEQ ID No. 2, Ser at position 56 is replaced by Val, Leu at position 143 is replaced by Phe, Lys at position 349 is replaced by Arg, Cys at position 376 is replaced by Pro, and Lys at position 526 is replaced by His;
[0138] (31) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, and Lys at position 349 is replaced by Arg;
[0139] (32) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 128 is replaced by His, Ala at position 146 is replaced by Arg, Ala at position 209 is replaced by Val, Gln at position 210 is replaced by Leu, and Lys at position 151 is replaced by Arg;
[0140] (33) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, Lys at position 349 is replaced by Arg, and Leu at position 143 is replaced by Phe;
[0141] (34) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, Lys at position 349 is replaced by Arg, Leu at position 143 is replaced by Phe, and Ser at position 56 is replaced by Val;
[0142] (35) In the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, Lys at position 349 is replaced by Arg, Leu at position 143 is replaced by Phe, Ser at position 56 is replaced by Val, and Lys at position 526 is replaced by His.
[0143] Example 7 Fermentation preparation of recombinant thioether monooxygenase mutants
[0144] The recombinant expression transformant containing the thioether monooxygenase mutant obtained in Example 1 was inoculated into LB medium containing 50 μg / mL kanamycin, and cultured on a shaking table at 37°C for 12 hours as a seed solution. The fermenter temperature and stirring speed were set to 37°C and 400rpm, respectively, and the ventilation volume was adjusted to 1vvm (3L / min). After the parameters of the fermenter were stabilized, 200mL of seed solution was inoculated into a fermenter containing 3L of culture medium (5g / L glycerol, 5g / L peptone, 5g / L yeast extract, 3g / L Na2HPO4, 0.7g / L Na2SO4, 3.4g / L KH2PO4, 0.25g / L MgSO4, 2.7g / L NH4Cl) under flame protection, and fermentation began. As the cells grow, dissolved oxygen (DO) decreases. When DO drops below 30%, the stirring speed is increased until the speed is increased to 500rpm. During the fermentation process, ammonia water is added to control the pH to about 7.0. After 2 hours of fermentation, samples were taken every 1 hour to detect the cell concentration (OD 600After 4 hours of cultivation, carbon and nitrogen sources (250 g / L glycerol, 60 g / L peptone, 60 g / L yeast extract) were added at a flow rate of 35 mL / h. After 5 hours of cultivation, the fermentation tank feed temperature was adjusted to 25 °C, and the feed rate was reduced to 27 mL / h. After 5.5 hours of cultivation, IPTG aqueous solution (mother liquor concentration 1 M, final concentration 0.2 mM) was added to induce the expression of the target protein. After induced expression, samples were taken every 2 hours to measure the OD 600 10 h after induction, the fermentation was terminated. The fermentation broth was centrifuged to obtain 200 g of resting cells.
[0145] Example 8 Preparation of cell lysate, lyophilized cells and lyophilized enzyme powder of recombinant thioether monooxygenase mutant
[0146] 100 g of the recombinant cells harvested in Example 4 were freeze-dried to obtain 25 g of freeze-dried cells containing the thioether monooxygenase mutant. 80 g of the harvested recombinant cells were suspended in 0.5 L of buffer, crushed by high-pressure homogenization, and the supernatant was collected by centrifugation to obtain a crude enzyme solution of the recombinant thioether monooxygenase mutant. The collected crude enzyme solution was frozen at -80°C, and then low-temperature dried using a vacuum freeze dryer to obtain 10 g of freeze-dried enzyme of the recombinant thioether monooxygenase mutant. The obtained freeze-dried enzyme powder was stored in a 4°C refrigerator for convenient use.
[0147] Example 9 Thioether monooxygenase AcPSMO M25 Co-expression of 10 g / L omeprazole thioether with isopropanol dehydrogenase catalyzes asymmetric oxidation
[0148] Reaction system (10 mL): omeprazole sulfide (10 g / L), isopropanol (10% v / v) and NAD + (0.1 mM), thioether monooxygenase AcPSMO constructed and prepared in Examples 4 and 7 M25 and isopropanol dehydrogenase co-expressing cells (100 g / L), phosphate buffer (100 mM, pH 8.0). Magnetic stirring, the reaction temperature is controlled at 30 ° C in a water bath. After 8 hours of reaction, 0.5 mL of the reaction solution is sampled and 0.5 mL of ethyl acetate is added for extraction. 0.3 mL of the extract is added to anhydrous sodium sulfate for drying, and the ethyl acetate is evaporated and then 1 mL of ethanol is added for dissolution. The substrate conversion rate and product ee are determined by the HPLC analysis method described in Example 6. The substrate conversion rate is greater than 99% after 8 hours of reaction, and the product ee value is greater than 99% (S).
[0149] Example 10 Thioether monooxygenase AcPSMO M31 Asymmetric oxidation of 20 g / L omeprazole sulfide catalyzed by cell disruption solution
[0150] Reaction system (10 mL): omeprazole sulfide (20 g / L), methanol (10% v / v), sodium formate (100 mM), NAD + (0.2 mM), thioether monooxygenase AcPSMO prepared in Examples 7 and 8 M31 Cell disruption solution (3U), formate dehydrogenase cell disruption solution (6U), phosphate buffer (100mM, pH 8.0). Magnetic stirring, the reaction temperature was controlled at 30°C in a water bath. After 12 hours of reaction, 0.5mL of the reaction solution was sampled and added with 0.5mL of ethyl acetate for extraction. 0.3mL of the extract was added with anhydrous sodium sulfate for drying, the ethyl acetate was evaporated, and then 1mL of ethanol was added for dissolution. The substrate conversion rate and product ee were determined by the HPLC analysis method described in Example 6. After 12h of reaction, the substrate conversion rate was greater than 99%, and the product ee value was greater than 99% (S).
[0151] Example 11 Thioether monooxygenase AcPSMO M35 Freeze-dried enzyme powder catalyzes asymmetric oxidation of 30g / L omeprazole sulfide
[0152] Reaction system (10 mL): omeprazole sulfide (30 g / L), methanol (10% v / v), glucose (200 mM) and NAD + (0.2 mM). Thioether monooxygenase AcPSMO prepared in Examples 7 and 8 M35 Lyophilized enzyme powder (4U), lyophilized glucose dehydrogenase powder (10U), phosphate buffer (500mM, pH 8.0).
[0153] The reaction temperature was controlled at 30°C with magnetic stirring and a water bath. After 24 hours of reaction, 0.5 mL of the reaction solution was sampled and added with 0.5 mL of ethyl acetate for extraction. 0.3 mL of the extract was added with anhydrous sodium sulfate for drying, and the ethyl acetate was evaporated and removed. Then, 1 mL of ethanol was added for dissolution, and the substrate conversion rate and product ee were determined by the HPLC analysis method described in Example 6. The substrate conversion rate was greater than 99% after 24 hours of reaction, and the product ee value was greater than 99% (S).
[0154] Example 12 Thioether monooxygenase AcPSMO in 1L reaction system M35 Co-expression of formate dehydrogenase and omeprazole sulfide catalyzes asymmetric oxidation of 30 g / L omeprazole sulfide
[0155] A 1 L reaction was carried out in a 3 L fermenter. The reaction system contained: omeprazole thioether (30 g / L), methanol (10% v / v), sodium formate (100 mM) and NAD + (0.1 mM), thioether monooxygenase AcPSMO constructed and prepared in Examples 4 and 7 M35and formate dehydrogenase co-expression cells (150 g / L), phosphate buffer (200 mM, pH 8.0). The mechanical stirring speed is 300 rpm, and the reaction temperature is controlled at 30°C by a water bath. After reacting for 24 hours, 0.5 mL of the reaction solution is sampled and added with 0.5 mL of ethyl acetate for extraction. 0.3 mL of the extract is added with anhydrous sodium sulfate for drying, and the ethyl acetate is evaporated and removed. Then 1 mL of ethanol is added for dissolution, and the substrate conversion rate and product ee are determined by the HPLC analysis method described in Example 6. The substrate conversion rate is greater than 99% after reacting for 24 hours, and the product ee value is greater than 99% (S).
[0156] The sequence information involved in the present invention is as follows:
[0157] SEQ ID No.1:
[0158]
[0159] MTQKMDFDAIIIGAGFGGLYSLKKLRDDFNLKVRAFDRATEVGGTWFWNQYPGAYSDSETHLYCYSWDKELLQEMEIKRKYISQPDVLAYLKRVADKHDLRKDIQFETGIRSAYFDEENSFWNVTTENDEKFTARFLITALGPLAAPNLPKIKGIETFKGELHHTSRWPKDVTFSGKRVGVIGTGSTGVQVITAIASQVKHLTVFQRSAQYSVPIGNVVMSETDVAKIKENYDQIWENVWNSALGYGLNESTLPTMSVSAEERDKIFEKAWQEGGGLRFMFETFGDIAVDETANIEAQNFIKKKISEIVKDPFVAKKLTPTDLYACRPLCDSGYYEVFNRDNVSLEDVKANPIVEIKEDCVVTADGVEHKLDMLICATGFDAVDGSYKRIDIRGKDGISIKDYWKDGPNSYLGMMVSNFPNMFMVFGPNGPLANSPPIIETQVRWIADLIGYAEDHQINQIEATKDAVDNWTNTCSDIANKTLFAKAKCRIFGANVSGKKNTVYLYMGGLKEYRNQISEVSNNNYKGCLLKQSVKKTNLIES
[0160] SEQ ID No.3:
[0161] CAG CCATAT ATGACTCAAAAAATGGATTT
[0162] SEQ ID No.4:
[0163] CGC AAGCTT TTAAGATTCTATAAGGTTGG
[0164] SEQ ID No.5:
[0165] TCCTGATCACCGCGCTGGGTNNKCTGGCGGCGCCGAACCTGCC
[0166] SEQ ID No.6:
[0167] GGCAGGTTCGGCGCCGCCAGMNNACCCAGCGCGGTGATCAGGA
[0168] SEQ ID No.7:
[0169] TCACCGCGCTGGGTCTGCTGNNKGCGCCGAACCTGCCGAAAAT
[0170] SEQ ID No.8:
[0171] ATTTTCGGCAGGTTCGGCGCMNNCAGCAGACCCAGCGCGGTGA
[0172] SEQ ID No.9:
[0173] CCGCGCTGGGTCTGCTGGCGNNKCCGAACCTGCCGAAAATTAA
[0174] SEQ ID No.10:
[0175] TTAATTTTCGGCAGGTTCGGMNNCGCCAGCAGACCCAGCGCGG
[0176] SEQ ID No.11:
[0177] TGGGTCTGCTGGCGGCGCCGNNKCTGCCGAAAATTAAGGGCAT
[0178] SEQ ID No.12:
[0179] ATGCCCTTAATTTTCGGCAGMNNCGGCGCCGCCAGCAGACCCA
[0180] SEQ ID No.13:
[0181] GTCTGCTGGCGGCGCCGAACNNKCCGAAAATTAAGGGCATCGA
[0182] SEQ ID No.14:
[0183] TCGATGCCCTTAATTTTCGGGMNNTTCGGCGCCGCCAGCAGACSEQ ID No.15:
[0184] TGGCGGCGCCGAACCTGCCGNNKATTAAGGGCATCGAGACCTTSEQ ID No.16:
[0185] AAGGTCTCGATGCCCTTAATMNNCGGCAGGTTCGGCGCCGCCASEQ ID No.17:
[0186] AACATTTAACAGTATTTCAANNKTCTGCTCAATACAGTGTGCCSEQ ID No.18:
[0187] GGCACACTGTATTGAGCAGAMNNTTGAAATACTGTTAAATGTTSEQ ID No.19:
[0188] ATTTAACAGTATTTCAACGTNNKGCTCAATACAGTGTGCCTATSEQ ID No.20:
[0189] ATAGGCACACTGTATTGAGCMNNACGTTGAAATACTGTTAAATSEQ ID No.21:
[0190] TAACAGTATTTCAACGTTCTNNKCAATACAGTGTGCCTATTGGSEQ ID No.22:
[0191] CCAATAGGCACACTGTATTGMNNAGAACGTTGAAATACTGTTASEQ ID No.23:
[0192] CAGTATTTCAACGTTCTGCTNNKTACAGTGTGCCTATTGGTAASEQ ID No.24:
[0193] TTACCAATAGGCACACTGTAMNNAGCAGAACGTTGAAATACTG。
Claims
1. A thioether monooxygenase mutant, characterized in that: The amino acid sequence of the mutant is selected from any one of the following: (1) replacing Ser at position 56 of the amino acid sequence shown in SEQ ID No. 2 with Val; (2) replacing Glu at position 70 of the amino acid sequence shown in SEQ ID No. 2 with Thr; (3) replacing Asn at position 123 of the amino acid sequence shown in SEQ ID No. 2 with Arg; (4) replacing Asn at position 128 of the amino acid sequence shown in SEQ ID No. 2 with His; (5) replacing Thr at position 133 of the amino acid sequence shown in SEQ ID No. 2 with Leu; (6) replacing Leu at position 143 of the amino acid sequence shown in SEQ ID No. 2 with Phe; (7) replacing Ala at position 145 of the amino acid sequence shown in SEQ ID No. 2 with Gly; (8) replacing Ala at position 146 of the amino acid sequence shown in SEQ ID No. 2 with Arg; (9) replacing Asn at position 148 of the amino acid sequence shown in SEQ ID No. 2 with Trp; (10) replacing Leu at position 149 of the amino acid sequence shown in SEQ ID No. 2 with Phe; (11) replacing Lys at position 151 of the amino acid sequence shown in SEQ ID No. 2 with Arg; (12) replacing Arg at position 207 of the amino acid sequence shown in SEQ ID No. 2 with Lys; (13) replacing Ser at position 208 of the amino acid sequence shown in SEQ ID No. 2 with Asp; (14) replacing Ala at position 209 of the amino acid sequence shown in SEQ ID No. 2 with Val; (15) replacing Gln at position 210 of the amino acid sequence shown in SEQ ID No. 2 with Leu; (16) replacing Lys at position 349 of the amino acid sequence shown in SEQ ID No. 2 with Arg; (17) replacing Cys at position 376 of the amino acid sequence shown in SEQ ID No. 2 with Pro; (18) replacing Lys at position 526 of the amino acid sequence shown in SEQ ID No. 2 with His; (19) The 56th Ser in the amino acid sequence shown in SEQ ID No. 2 is replaced by Val, and the 143rd Leu is replaced by Phe; (20) the Asn at position 123 of the amino acid sequence shown in SEQ ID No. 2 is replaced by Arg, and the Ala at position 145 is replaced by Gly; (21) the Asn at position 128 of the amino acid sequence shown in SEQ ID No. 2 is replaced by His, and the Ala at position 146 is replaced by Arg; (22) replacing Leu at position 149 with Phe and Ser at position 208 with Asp in the amino acid sequence shown in SEQ ID No. 2; (23) the 151st Lys of the amino acid sequence shown in SEQ ID No. 2 is replaced by Arg, and the 210th Gln is replaced by Leu; (24) The 349th Lys in the amino acid sequence shown in SEQ ID No. 2 is replaced by Arg, and the 526th Lys is replaced by His; (25) in the amino acid sequence shown in SEQ ID No. 2, the Ser at position 56 is replaced by Val, the Leu at position 143 is replaced by Phe, and the Lys at position 349 is replaced by Arg; (26) in the amino acid sequence shown in SEQ ID No. 2, Glu at position 70 is replaced by Thr, Asn at position 148 is replaced by Trp, and Cys at position 376 is replaced by Pro; (27) in the amino acid sequence shown in SEQ ID No. 2, Ser at position 56 is replaced by Val, Leu at position 143 is replaced by Phe, Lys at position 349 is replaced by Arg, and Cys at position 376 is replaced by Pro; (28) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, and Ser at position 208 is replaced by Asp; (29) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 128 is replaced by His, Ala at position 146 is replaced by Arg, Ala at position 209 is replaced by Val, and Gln at position 210 is replaced by Leu; (30) in the amino acid sequence shown in SEQ ID No. 2, Ser at position 56 is replaced by Val, Leu at position 143 is replaced by Phe, Lys at position 349 is replaced by Arg, Cys at position 376 is replaced by Pro, and Lys at position 526 is replaced by His; (31) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, and Lys at position 349 is replaced by Arg; (32) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 128 is replaced by His, Ala at position 146 is replaced by Arg, Ala at position 209 is replaced by Val, Gln at position 210 is replaced by Leu, and Lys at position 151 is replaced by Arg; (33) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, Lys at position 349 is replaced by Arg, and Leu at position 143 is replaced by Phe; (34) in the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, Lys at position 349 is replaced by Arg, Leu at position 143 is replaced by Phe, and Ser at position 56 is replaced by Val; (35) In the amino acid sequence shown in SEQ ID No. 2, Asn at position 123 is replaced by Arg, Ala at position 145 is replaced by Gly, Arg at position 207 is replaced by Lys, Ser at position 208 is replaced by Asp, Lys at position 349 is replaced by Arg, Leu at position 143 is replaced by Phe, Ser at position 56 is replaced by Val, and Lys at position 526 is replaced by His.
2. An isolated nucleic acid, characterized in that Encoding the thioether monooxygenase mutant as claimed in claim 1.
3. A recombinant expression vector, characterized in that: The recombinant expression vector comprises the nucleic acid according to claim 2.
4. A co-expression recombinant vector, characterized in that: The co-expression recombinant vector comprises the nucleic acid as claimed in claim 2 and a dehydrogenase gene.
5. A co-expression recombinant vector according to claim 4, characterized in that: The dehydrogenase is any one of formate dehydrogenase, glucose dehydrogenase and isopropanol dehydrogenase.
6. A recombinant expression transformant, characterized in that: Comprising the recombinant expression vector according to claim 3 or the co-expression recombinant vector according to claim 4.
7. A recombinant thioether monooxygenase mutant catalyst, characterized in that: Is any of the following: (1) culturing the recombinant expression transformant according to claim 6, and isolating transformant cells containing the thioether monooxygenase mutant according to claim 1; (2) culturing the recombinant expression transformant according to claim 6, isolating and crushing the crude enzyme solution containing the thioether monooxygenase mutant according to claim 1; (3) Cultivating the recombinant expression transformant according to claim 6, isolating and crushing the thioether monooxygenase mutant according to claim 1 to obtain a crude enzyme solution, and freeze-drying the crude enzyme solution to obtain a crude enzyme powder.
8. Use of the thioether monooxygenase mutant according to claim 1 or the recombinant thioether monooxygenase mutant catalyst according to claim 7, characterized in that: Application in catalyzing the asymmetric oxidation of the substrate omeprazole sulfide to prepare esomeprazole.
9. The use according to claim 8, characterized in that NADH or NAD needs to be added during the reaction + Any of; in the application, NADH is oxidized to NAD + , while using dehydrogenase to catalyze NAD + Reduced to NADH to realize the coenzyme cycle; the application also requires the presence of at least one of glucose, sodium formate, isopropanol and its corresponding dehydrogenase; the glucose corresponds to glucose dehydrogenase, the sodium formate corresponds to sodium formate dehydrogenase, and the isopropanol corresponds to isopropanol dehydrogenase.
10. The use according to claim 8, characterized in that The concentration of the substrate omeprazole sulfide is 1-30 g / L, the dosage of the glucose, sodium formate or isopropanol is 1-45 g / L, and the coenzyme NADH or NAD + The dosage is 0.1-0.5 mM; the dosage of the thioether monooxygenase mutant or the recombinant thioether monooxygenase mutant catalyst is 10-800 U / L, and the dosage of the dehydrogenase is 15-1200 U / L.
Citation Information
Patent Citations
Thioether monooxygenase and application thereof in preparation of chiral prazole drugs
CN112725297A
Thioether monooxygenase mutant and application thereof in preparation of chiral prazole medicine
CN116855463A
